Trial Profile
Phase II Trial Of Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2018 New trial record